| Title |
STAT inhibitors for cancer therapy
|
|---|---|
| Published in |
Journal of Hematology & Oncology, December 2013
|
| DOI | 10.1186/1756-8722-6-90 |
| Pubmed ID | |
| Authors |
Muhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen, Delong Liu |
| Abstract |
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Hungary | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 181 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | <1% |
| Netherlands | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 175 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 45 | 25% |
| Student > Master | 30 | 17% |
| Researcher | 21 | 12% |
| Student > Bachelor | 18 | 10% |
| Professor > Associate Professor | 10 | 6% |
| Other | 25 | 14% |
| Unknown | 32 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 41 | 23% |
| Medicine and Dentistry | 37 | 20% |
| Biochemistry, Genetics and Molecular Biology | 26 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 9% |
| Chemistry | 11 | 6% |
| Other | 16 | 9% |
| Unknown | 34 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 December 2019.
All research outputs
#4,434,542
of 22,733,113 outputs
Outputs from Journal of Hematology & Oncology
#328
of 1,189 outputs
Outputs of similar age
#53,344
of 306,767 outputs
Outputs of similar age from Journal of Hematology & Oncology
#5
of 16 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,767 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.